Who are BCD-263's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taltz, Cosentyx, Subcutaneous injection of Secukinumab, Secukinumab Auto-Injector, Ixekizumab Prefilled Syringe, Proactive TDM-based dosing of ixekizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bcd-263.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

BCD-263 — Competitive Intelligence Brief

BCD-263 (BCD-263) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-17A inhibitor (monoclonal antibody). Area: Immunology / Rheumatology.

phase 3 IL-17A inhibitor (monoclonal antibody) IL-17A Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

BCD-263 (BCD-263) — Biocad. BCD-263 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BCD-263 TARGET	BCD-263	Biocad	phase 3	IL-17A inhibitor (monoclonal antibody)	IL-17A
Taltz	ixekizumab	Eli Lilly	marketed	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cosentyx	secukinumab	Novartis	marketed	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Subcutaneous injection of Secukinumab	Subcutaneous injection of Secukinumab	Peking Union Medical College	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A (Interleukin-17A)
Secukinumab Auto-Injector	Secukinumab Auto-Injector	University of Pennsylvania	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Ixekizumab Prefilled Syringe	Ixekizumab Prefilled Syringe	Eli Lilly and Company	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Proactive TDM-based dosing of ixekizumab	Proactive TDM-based dosing of ixekizumab	University Hospital, Ghent	marketed	IL-17A inhibitor; monoclonal antibody	IL-17A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-17A inhibitor (monoclonal antibody) class)

Eli Lilly and Company · 2 drugs in this class
Celltrion · 1 drug in this class
Biocad · 1 drug in this class
Peking Union Medical College · 1 drug in this class
Professor Mikkel Østergaard · 1 drug in this class
University of Pennsylvania · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BCD-263 — Competitive Intelligence Brief. https://druglandscape.com/ci/bcd-263. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab